Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490762 · ClinicalTrials.gov registry record · Phase 1
Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01490762 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 35 participants.
The verdict
NCT01490762, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is an open-Label, Randomized Study in Healthy Normal Volunteers looking at exposure and effects (PK/PD) of multiple doses of Technosphere® Insulin (TI) using the Gen2C inhaler.
Interventions
- DRUG Regular Human Insulin
- DRUG Technosphere Insulin Inhalation Powder using the Gen2C inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01490762
The ClinicalTrials.gov registry entry for NCT01490762 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regular Human Insulin is the first listed.
NCT01490762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01490762 about?
NCT01490762 is a clinical study titled "Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler". This is an open-Label, Randomized Study in Healthy Normal Volunteers looking at exposure and effects (PK/PD) of multiple doses of Technosphere® Insulin (TI) using the Gen2C inhaler.
What is the current status of trial NCT01490762?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01490762?
The interventions under investigation include: Regular Human Insulin (DRUG), Technosphere Insulin Inhalation Powder using the Gen2C inhaler (DRUG).
Who is sponsoring clinical trial NCT01490762?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.